India’s pharmaceutical market grew by 11% year-on-year within the fourth quarter ended March, FY23, pushed primarily by sturdy gross sales of anti-infective and ache drugs as viral infections surged, in keeping with market analysis agency AWACS.
The volumes have been tepid in January, however with flu, Covid-19 and different viral infections spreading quick, February and March noticed spikes in volumes of anti-infectives, respiratory and ache medicines, AWACS stated in its report. The three therapies collectively account for about 30% of the home pharma market. The anti-infectives, led by amoxycillin and clavulanic acid mixtures, azithromycin and hospital anti-infectives noticed worth development of 33.7% for February and March, whereas volumes grew by 28%.
The respiratory medicines phase, pushed by cough syrups like ambroxol, levosalbutamol and guaifenesin mixtures, chlorpheniramine, dextromethorphan mixtures and budesonide, rotacaps and inhalers noticed worth and quantity development of greater than 50%. Paracetamol and different analgesics, too, joined the celebration, seeing about 20% worth and 13% quantity development. The general market grew by 9.3% to ₹1.85 lakh crore in FY23. The quantity development in the identical interval stood at 1.8%.
GSK’s Augmentin (amoxycillin and clavulanic acid) retained its high spot. Firms with sturdy anti-infective and respiratory portfolios like Cipla, Mankind, Macleods, Aristo and Glenmark grew by greater than 20% in March 2023.
